Loading clinical trials...
Loading clinical trials...
A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151
Conditions
Interventions
ASP2151
Placebo
Locations
1
France
Site FR1717
Paris, France
Start Date
September 1, 2005
Primary Completion Date
December 1, 2005
Completion Date
December 1, 2005
Last Updated
August 2, 2016
NCT04128189
NCT07378059
NCT06932523
NCT06903078
NCT06449547
NCT05424302
Lead Sponsor
Astellas Pharma Europe Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions